Tinea Unguium Market

DelveInsight's "Tinea Unguium — Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the tinea unguium, historical and forecasted epidemiology as well as the tinea unguium market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

The tinea unguium market report provides current treatment practices, emerging drugs, tinea unguium market share of the individual therapies, current and forecasted tinea unguium market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current tinea unguium treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom)
• Japan

Study Period: 2019–2032

Tinea Unguium Disease Understanding and Treatment Algorithm

The DelveInsight’s tinea unguium market report gives a thorough understanding of tinea unguium by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Tinea Unguium, a fungal infection of the nail, is the most common nail infection worldwide, causing discoloration and thickening of the affected nail plate. tinea unguium was initially thought to be caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by nondermatophyte molds (NDMs) are more prevalent than thought previously, especially in warmer climates.

Diagnosis

Diagnosis usually requires mycological laboratory confirmation. Dermoscopy can be helpful and also biopsy is an excellent diagnostic method in uncommon cases or when mycological test is negative.

Treatment

Several treatment options are available for treating tinea unguium, including oral antifungals, topical antifungals, and devices. Oral antifungals have higher treatment cure rates and shorter treatment periods than topical treatments but have adverse side effects such as hepatotoxicity and drug interactions. Terbinafine, itraconazole, and fluconazole are the most commonly used antifungals.

Tinea Unguium Epidemiology 

The tinea unguium epidemiology section provides insights about historical and current tinea unguium patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

Arenas et al. (2016), states that worldwide tinea Unguium prevalence ranges from 2% to 50%, and it represents about 30% of superficial mycotic infections and 50% of all nail disorders and mainly affects adults between 30 and 60 years of age.

The disease epidemiology covered in the report provides historical as well as forecasted tinea unguium epidemiology segmented as Diagnosed Prevalent Cases of Tinea Unguium, Diagnosed Prevalent Cases of Tinea Unguium by Subtypes, Diagnosed Prevalent Cases of Tinea Unguium by Severity and Treated Cases of Tinea Unguium in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- Tinea Unguium Epidemiology

This section provides glimpse of the tinea unguium epidemiology in the United States, EU4 (Germany, Spain, Italy, France) and United Kingdom, and Japan

Tinea Unguium Drug Chapters

The drug chapter segment of the tinea unguium report encloses the detailed analysis of tinea unguium marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the tinea unguium clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Tinea Unguium Marketed Drugs

Kerydin (tavaborole): Pfizer

In July 2014, the FDA approved Kerydin (tavaborole) for the treatment of tinea unguium of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).

Jublia/Clenafin (efinaconazole): Bausch Health

In July 2014, the FDA approved Jublia for the treatment of tinea Unguium of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Jublia is marketed under the brand name Clenafin (Kaken Pharmaceuticals) in Japan since 2014. The solution-based formula has low surface tension and keratin binding properties that increase penetrance through the nail plate. Safety studies have shown that this formulation is not associated with atopic dermatitis or contact sensitivity.

Note: Detailed Current therapies assessment will be provided in the full report of tinea unguium

Tinea Unguium Emerging Drugs

BB2603 (Blueberry Therapeutics) is squalene epoxidase inhibitor BB2603 in a spray formulation is currently ongoing Phase II trials for the treatment of tinea Unguium which is expected to be completed by December 2021. It is an innovative new treatment concept using nanotechnology to deliver terbinafine.

MOB015 (Moberg Pharma) is the next-generation nail fungus treatment targeting both over-the-counter (OTC) and prescription markets around the world. The company’s patented formulation technology facilitates delivery of high concentrations of a proven antifungal substance (terbinafine) into and through the nail, and has emollient and keratolytic properties that contribute to rapid, visible improvement.

Note: Detailed emerging therapies assessment will be provided in the full report of tinea unguium

Tinea Unguium Market Outlook

The market comprises a variety of options for the treatment for tinea unguium. Oral terbinafine hydrochloride (Lamisil) is the most common treatment for tinea unguium. These 250 mg tablets are taken once a day for 12 weeks. First approved in 1996 by the US FDA, it has been the mainstay with all its generic versions marketed since the patent expiry in 2007. Other components that make up the total revenue generated by systemic therapies include itraconazole, griseofulvin, fluconazole, and ketoconazole.

Key players such as Moberg Pharma, Blueberry Therapeutics, and Mycovia Pharmaceuticals   along with few others are involved in developing therapies for tinea unguium.

According to DelveInsight, tinea unguium market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of tinea unguium is very robust, many potential therapies are being investigated for the treatment of tinea unguium, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the tinea unguium market in the 7MM. Aside from that, the market size of tinea unguium may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of tinea unguium may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Tinea Unguium Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the tinea unguium market or expected to get launched in the market during the study period 2019-2032. The analysis covers Tinea unguium market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of tinea unguium.

Tinea Unguium Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses tinea unguium key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for tinea unguium emerging therapies.

Reimbursement Scenario in Tinea Unguium

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the tinea unguium domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or tinea unguium market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the tinea unguium Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview tinea unguium, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the tinea unguium epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for tinea unguium are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the tinea unguium market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global tinea unguium market

Report Highlights

• In the coming years, the tinea unguium market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence tinea unguium R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for tinea unguium. The launch of emerging therapies will significantly impact the tinea unguium market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for tinea unguium
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Tinea Unguium Report Insights

• Patient Population
• Therapeutic Approaches
• Tinea Unguium Pipeline Analysis
• Tinea Unguium Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Tinea Unguium Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Tinea Unguium Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Tinea Unguium Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the tinea unguium drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the tinea unguium total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest tinea unguium market size during the forecast period (2019-2032)?
• At what CAGR, the tinea unguium market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the tinea unguium market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the tinea unguium market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of tinea unguium?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• What is the historical tinea unguium patient pool in seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• What would be the forecasted patient pool of tinea unguium in seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about tinea unguium?
• Out of all 7MM countries, which country would have the highest prevalence population of tinea unguium during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the tinea unguium treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of tinea unguium in the USA, Europe, and Japan?
• What are the tinea unguium marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of tinea unguium?
• How many therapies are in-development by each company for tinea unguium treatment?
• How many are emerging therapies in mid-stage, and late stage of development for tinea unguium treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the tinea unguium therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for tinea unguium and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for tinea unguium?
• What are the global historical and forecasted markets of tinea unguium?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the tinea unguium market
• Organize sales and marketing efforts by identifying the best opportunities for tinea unguium in the US, Europe (Germany, Spain, Italy, France and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the tinea unguium market
• To understand the future market competition in the tinea unguium market